Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical ...
Financial News USA (press release) - La Puente,CA,USA
announced recently that they have enrolled and dosed the first patients in the TYSABRI® (natalizumab) monotherapy safety extension study program in multiple ...

Elan and Biogen Idec resume safety study on Tysabri
Ireland Online - Dublin,Ireland
Elan Corporation and its partner Biogen Idec have confirmed that they have resumed a safety study on their controversial MS drug Tysabri. ...
See all stories on this topic

Healthcare Industry Today Offers Extended News Coverage of Tysabri ...
PR Newswire (press release) - New York,NY,USA
See: * Drugs News - http://www.healthcareindustrytoday.com/category/Drugs/pr * Tysabri News - http://www.healthcareindustrytoday.com/news/Tysabri/pr * Lipitor ...
See all stories on this topic